Group A and C meningococcal polysaccharide vaccine is the product developed independently by Walvax. Walvax obtained the Drug Registration Approval issued by the State Food and Drug Administration on March, 2012 (No.: 2012S00183, Drug Approval No.: Guoyao Zhunzi S20120004). The product was on market officially in December 2012.
This vaccine is a freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitides Group A and Group C, Mixed lactose as stabilizer made of white loose lyophilized vaccine. This product is only recommended for Children and adults over the age of 2 years. This vaccine can produce a humoral immune, and it is used to prevent disease caused by the bacteria named “Neisseria meningitidis groups A and group C”.